Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study

BACKGROUND: Ustekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn’s disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab on the immune system, we investigated the effect on skin and gut microbiota...

Descripción completa

Detalles Bibliográficos
Autores principales: Rob, Filip, Schierova, Dagmar, Stehlikova, Zuzana, Kreisinger, Jakub, Roubalova, Radka, Coufal, Stepan, Mihula, Martin, Jackova, Zuzana, Kverka, Miloslav, Thon, Tomas, Kostovcikova, Klara, Bajer, Lukas, Drastich, Pavel, Hercogova, Jana Tresnak, Novakova, Michaela, Kolar, Martin, Vasatko, Martin, Lukas, Milan, Tlaskalova-Hogenova, Helena, Jiraskova Zakostelska, Zuzana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803183/
https://www.ncbi.nlm.nih.gov/pubmed/36584073
http://dx.doi.org/10.1371/journal.pone.0277576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803183/
https://www.ncbi.nlm.nih.gov/pubmed/36584073
http://dx.doi.org/10.1371/journal.pone.0277576

Ejemplares similares